Claim · 2021-12-07 · announcement · Stated in source · Supported

Recursion announced on 7 December 2021 a collaboration with Roche and Genentech in neuroscience and an oncology indication, under which it would receive an upfront payment of $150 million, and stated that Roche and Genentech may initiate up to 40 programs, each of which could yield more than $300 million in milestones if successfully developed and commercialized.

One recorded claim. The claim panel gives its qualification, the source passages with their place in each source, and how it was checked.

What it connects

Recursion Pharmaceuticals → announced a partnership with → Roche

Where it appears

No collection page holds this claim. It is listed with its records in the explorer.

Claim and evidence

Recursion Pharmaceuticalsannounced a partnership with ↓Roche

Machine-checked, not reviewed by an editorStated in sourceSupported

Supporting evidence: primary · 1 source

Date: 2021-12-07 · announcement Records dated 2021 →
Activity stage: announced

Scope and limitsAnnounced terms as Recursion states them. The milestone figures are conditional and per programme; they are not totalled, and the record does not establish payments received. Genentech is a party with Roche (the release names Genentech as a member of the Roche Group).

The evidence 02

primary sourceSupports the claim

Recursion Announces Transformational Collaboration with Roche and Genentech in Neuroscience and Oncology

Recursion Pharmaceuticals, Inc. (Exhibit 99.1 to Form 8-K) · 2021-12-07

Cite the original source

Cite the original document, not Selekoa. Check these details against it.

Source excerpt

“Under the terms of the agreement, Recursion will receive an upfront payment of $150 million and is eligible for additional performance-based research milestones. Under the collaboration, Roche and Genentech (combined) may initiate up to 40 programs”

Location in source first paragraph

How it was read Retrieved directly from the publisher

Machine-checked · 2026-10-30

Source details and check notes

Authors: Recursion Pharmaceuticals, Inc. (Exhibit 99.1 to Form 8-K)
Version: Retrieved for the candidate pack on 2026-10-30 (SHA-256 48fdf37fcc2665c56610cee9ac3bc11cec1085cba4b7bccc27a9961c8deef1de). Exhibit 99.1 to Form 8-K filed 2021-12-07, accession 0001193125-21-349657, as served by SEC EDGAR on 2026-10-30. Its wording can change; earlier wording is not authenticated.
Canonical address: Open the canonical source ↗
Accessed: 2026-10-30
Language: English (en)
Attribution: Recursion Pharmaceuticals, Inc. (Exhibit 99.1 to Form 8-K), “Recursion Announces Transformational Collaboration with Roche and Genentech in Neuroscience and Oncology”, 2021-12-07.
Reuse: No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution.
Check notes: Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (36 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. A cross-family machine check (2026-10-30, item A17) answered the record’s question blind from fresh retrievals and agreed with the record. No human editorial review.

primary sourceSupports the claim

Recursion Announces Transformational Collaboration with Roche and Genentech in Neuroscience and Oncology

Recursion Pharmaceuticals, Inc. (Exhibit 99.1 to Form 8-K) · 2021-12-07

Cite the original source

Cite the original document, not Selekoa. Check these details against it.

Source excerpt

“each of which, if successfully developed and commercialized, could yield more than $300M in development, commercialization and net sales milestones for Recursion”

Location in source first paragraph

How it was read Retrieved directly from the publisher

Machine-checked · 2026-10-30

Source details and check notes

Authors: Recursion Pharmaceuticals, Inc. (Exhibit 99.1 to Form 8-K)
Version: Retrieved for the candidate pack on 2026-10-30 (SHA-256 48fdf37fcc2665c56610cee9ac3bc11cec1085cba4b7bccc27a9961c8deef1de). Exhibit 99.1 to Form 8-K filed 2021-12-07, accession 0001193125-21-349657, as served by SEC EDGAR on 2026-10-30. Its wording can change; earlier wording is not authenticated.
Canonical address: Open the canonical source ↗
Accessed: 2026-10-30
Language: English (en)
Attribution: Recursion Pharmaceuticals, Inc. (Exhibit 99.1 to Form 8-K), “Recursion Announces Transformational Collaboration with Roche and Genentech in Neuroscience and Oncology”, 2021-12-07.
Reuse: No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution.
Check notes: Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (22 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. A cross-family machine check (2026-10-30, item A17) answered the record’s question blind from fresh retrievals and agreed with the record. No human editorial review.

Status and meaning

Editorial status. Not reviewed by an editor. An exploratory record that no editor has accepted. This status does not say whether a person has read any linked passage. Each evidence record above shows how it was checked.

Relation. An organisation announced a collaboration or partnership with a named counterparty, as the announcement states it (stage announced). It is not evidence that the work was performed, that a payment was made or that the arrangement continues; an “up to” amount stays in the statement.

Date. Date of Recursion's press release.

Record ID aib-co-recursion-roche-genentech-2021